Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia : A double blind, placebo controlled trial.

Trial Profile

Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia : A double blind, placebo controlled trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Weight gain
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2013 Status changed from active, no longer recruiting to completed.
    • 01 Jun 2013 Primary endpoint 'Body-mass-index' has been met.
    • 01 Jun 2013 Primary endpoint 'Bodyweight' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top